NICE to be sidelined on cost effectiveness – once again
May 17, 2012Sales and Marketing NICE, VBP
Health secretary Andrew Lansley has confirmed that NICE will no longer direct the NHS on the cost effectiveness of drugs. …
NICE comes out fighting against appraisal delays story
May 17, 2012Sales and Marketing Daily Mail, Dillon, NHS, NICE, Pfizer, Victrelis
NICE has criticised a report that says the watchdog has taken up to nine years to appraise certain drugs. The …
Medivir appoints commercial executive vice president
May 17, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Juserius, Medivir
Research-based speciality firm Medivir has appointed Henric Juserius to be the new head of the company’s commercial activities. Juserius who …
Torisel fails in head-to-head study with Nexavar
May 16, 2012Research and Development, Sales and Marketing Bayer, Nexavar, Pfizer, Torisel, inlyta, rcc
Pfizer’s kidney cancer drug Torisel has failed to best Bayer’s Nexavar in a head-to-head trial. The Phase III study was …
Pharma funds drug discovery partnership
May 16, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Dundee, MRC, drug discovery, funding, partnerships, pharma
Half a dozen pharma firms are contributing £14.4 million to work by Dundee University and the Medical Research Council (MRC) on …
Merck KGaA’s colon cancer drug fails trial
May 16, 2012Research and Development, Sales and Marketing Erbitux, Merck KGaA, Merck Serono, colon cancer
Merck KGaA has suffered a setback with key brand Erbitux as the colerectal cancer drug failed in a late-stage trial. …
Capturing the Brazilian pharma opportunity
May 16, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brazil, McKinsey, market access, middle class, pharma
Many multinationals are hungry to sell their goods and services to the emerging markets’ growing middle class, comprising nearly two …
Price cut sways NICE on Zytiga
May 16, 2012Sales and Marketing Jevtana, NICE, Zytiga, prostate cancer
NICE is recommending Janssen’s prostate cancer pill Zytiga, reversing its previous stance. In its final guidance, the watchdog is recommending …
Open Health appoints new digital designer
May 16, 2012Business Services, Medical Communications, Sales and Marketing Open Health
Leo Jacobs has been appointed by Open Health as a digital designer to sit within its OPEN Source team. The …
Merck KGaA sets out savings target as staff threaten to strike
May 15, 2012Research and Development, Sales and Marketing Merck KGaA, R&D, Serono, cuts
Merck KGaA has outlined its plan to make €300 million in savings from its Serono drugs unit, with over half …
CoreLab Partners collaborates at industry conferences worldwide
May 15, 2012Research and Development
Princeton, NJ May 15, 2012 – CoreLab Partners, Inc, a leading independent core lab providing centralized cardiac safety services and …
Genentech taken to task over Avastin production
May 15, 2012Manufacturing and Production Genentech, Phil Taylor, avastin, manufacturing
FDA inspections of a manufacturing facility for Roche/Genentech’s cancer drug Avastin (bevacizumab) uncovered a number of deficiencies which could increase …
ABPI launches new NHS partnership guide
May 15, 2012Medical Communications, Sales and Marketing ABPI, COPD, NHS, code
The Association of the British Pharmaceutical Industry has launched a new guide to explain how pharma and the NHS can …
GlaxoSmithKline to acquire Cellzome for £61 million
May 15, 2012Research and Development, Sales and Marketing Cellzome, Domantis, GSK, R&D
GlaxoSmithKline will expand its platform technology capability with the acquisition of a chemical proteomics company. GSK will acquire those shares …
Synthetic Biologics appoints Carol Reed
May 15, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Carol Reed, Synthetic
Synthetic Biologics has appointed Carol Reed as senior vice president of Clinical & Regulatory Affairs. In this position Reed will …
Gilenya to stay on US market – but with new safety warnings
May 15, 2012Sales and Marketing EMA, FDA, Novartis, PML, gilenya
The FDA says that Novartis’ multiple sclerosis pill Gilenya should stay on the market, but has added new safety warnings …
Scottish watchdog rejects Yervoy
May 14, 2012Sales and Marketing BMS, Cancer, NICE, SMC, Yervoy, melanoma
The Scottish Medicines Consortium is not recommending Bristol-Myers Squibb’s melanoma treatment Yervoy. The SMC said that Yervoy (ipilimumab), which has …
New Quad HIV pill on track for FDA approval
May 14, 2012Research and Development, Sales and Marketing BMS, Compera, FDA, Gilead, HIV, The Quad
Gilead Sciences’ four-in-one HIV pill has been given the thumbs up by an FDA advisory group. The US regulator is …
Obesity drugs vie for approval as FDA panel backs lorcaserin
May 14, 2012Research and Development, Sales and Marketing Arena, Eisai, FDA, Qnexa, lorcaserin, obesity
An FDA panel has recommended Arena’s obesity drug lorcaserin, setting up a showdown with Vivus’ Qnexa. Qnexa was recommended by an FDA panel …
BASF buys Equateq to tap into growing health ingredient business
May 11, 2012Manufacturing and Production BASF, Equateq, Phil Taylor, omega-3
BASF has said it intends to buy Equateq, a UK-based specialist in lipid ingredients that represent a ‘global growing market’, …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
